Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
2
40%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(1)
Other(3)

Detailed Status

unknown3
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

unknown360%
completed120%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

NCT05116891
terminatedphase_2

First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma

NCT03324282
unknownphase_1

A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment

NCT04872634
unknownphase_2

Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis

NCT01646736
unknownphase_1

Oral OKT3 in Combination With Beta-D-Glucosylceramide

NCT00619372

Clinical Trials (5)

Showing 5 of 5 trials
NCT05116891Phase 1

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Completed
NCT03324282Phase 2

First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma

Terminated
NCT04872634Phase 1

A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment

Unknown
NCT01646736Phase 2

Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis

Unknown
NCT00619372Phase 1

Oral OKT3 in Combination With Beta-D-Glucosylceramide

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5